JBCHEPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.1
| Stock Code | JBCHEPHARM | Market Cap | 30,382 Cr. | Current Price | 1,892 ₹ | High / Low | 1,939 ₹ |
| Stock P/E | 41.8 | Book Value | 238 ₹ | Dividend Yield | 0.82 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,839 ₹ | DMA 200 | 1,759 ₹ |
| Chg in FII Hold | -0.76 % | Chg in DII Hold | -0.12 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 56.0 | MACD | 11.8 | Volume | 3,25,819 | Avg Vol 1Wk | 1,97,811 |
| Low price | 1,303 ₹ | High price | 1,939 ₹ | PEG Ratio | 1.75 | Debt to equity | 0.01 |
| 52w Index | 92.5 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 29.1 |
📊 Analysis: JBCHEPHARM is trading at ₹1,892, above both its 50 DMA (₹1,839) and 200 DMA (₹1,759), showing strong technical support. RSI at 56.0 indicates neutral-to-positive momentum, while MACD at 11.8 confirms bullish undertone. Current volume (3.25 lakh) is higher than the 1-week average (1.97 lakh), suggesting strong intraday participation. Fundamentals remain solid with ROCE 25.9% and ROE 20.2%, supported by low debt-to-equity (0.01). Intraday setup favors buying near support with potential for quick profit booking.
💡 Optimal Buy Price: ₹1,885–₹1,895 (near support zone).
🎯 Profit-Taking Levels: ₹1,915–₹1,930 (short-term resistance).
🛡️ Stop-Loss: ₹1,870 (to protect against downside risk).
⏱️ Exit Strategy if Already Holding: Exit if price fails to sustain above ₹1,890 with weakening momentum or if volume drops sharply. If intraday momentum continues, consider booking profits around ₹1,915–₹1,930. Avoid holding beyond resistance unless strong breakout signals appear.
✅ Positive
- Trading above both 50 DMA and 200 DMA, showing strong technical support.
- High ROCE (25.9%) and ROE (20.2%) indicate efficient capital use.
- Low debt-to-equity ratio (0.01) ensures financial stability.
- EPS of ₹46.5 reflects strong earnings capability.
- Volume significantly higher than average, supporting intraday momentum.
⚠️ Limitation
- High P/E of 41.8 compared to industry PE of 29.1, suggesting overvaluation.
- PEG ratio of 1.75 indicates moderate growth relative to valuation.
- Minor decline in quarterly PAT (₹179 Cr vs ₹200 Cr).
- Institutional confidence slightly reduced with FII (-0.76%) and DII (-0.12%) stake decreases.
📉 Company Negative News
- Quarterly PAT declined compared to previous quarter.
- Stock trading close to 52-week high (₹1,939), limiting upside potential.
📈 Company Positive News
- Quarterly profit variation shows 14.6% growth YoY.
- Strong fundamentals with high ROCE and ROE.
- Dividend yield of 0.82% provides shareholder returns.
🏭 Industry
- Industry PE at 29.1 is lower than JBCHEPHARM’s PE, highlighting relative overvaluation.
- Pharma sector remains resilient with steady demand outlook.
🔎 Conclusion
JBCHEPHARM shows strong technicals and solid fundamentals, making it a good candidate for intraday trading. Buying near support with tight stop-loss and booking profits quickly around resistance levels is advisable. Momentum indicators and high volume favor tactical intraday trades with limited holding beyond resistance.